Liver-Targeted Antigen Conjugates for Rapid Antibody Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for transplant rejection, autoimmune diseases, and immune responses against therapeutic agents lack effective methods to target antigens for tolerization and clearance, particularly utilizing the liver's role in immune tolerance and blood purification.
Innovation Solution
Development of compositions comprising compounds with a liver-targeting moiety, such as galactose or N-acetylgalactosamine, linked to antigens or antibodies through specific linkers, to facilitate uptake by liver cells like hepatocytes and LSECs, promoting tolerization and clearance of unwanted immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for transplant rejection and autoimmune diseases, then existing therapies can provide some level of immune suppression, but they lack effective targeting to liver cells for optimal tolerization and clearance
Solution Approach 1:
The patent uses asialoglycoprotein receptors (ASGPRs) as intermediary targets on liver cells. By conjugating antigens or antibodies to ligands that bind ASGPRs, the therapy achieves specific targeting to liver cells without directly modifying the liver cells themselves. This intermediary approach enables selective delivery to the desired location while maintaining the simplicity of the treatment protocol.
Solution Approach 2:
The patent modifies the pharmacokinetic parameters of the therapeutic agent by conjugating it to ASGPR-targeting ligands. This changes the distribution and uptake characteristics of the agent, enabling it to be selectively taken up by liver cells through ASGPR-mediated endocytosis. The parameter change allows the same basic therapeutic molecule to achieve organ-specific targeting and enhanced clearance.
2Productivity
If liver-targeting moieties are added to compositions, then uptake by liver cells is enhanced, but the complexity of the composition increases
Solution Approach 1:
The patent segments the therapeutic composition into distinct functional components: the therapeutic agent (antigen or antibody), the linker moiety, and the ASGPR-targeting ligand. This segmentation allows each component to be optimized independently - the therapeutic agent for its biological activity, the linker for stability and orientation, and the ligand for targeting efficiency. The modular structure simplifies the overall design while enabling enhanced liver cell uptake.
3Quantity of substance
If conventional clearance methods are used, then some antibody removal occurs, but the concentration reduction is insufficient and takes too long
Solution Approach 1:
The patent performs preliminary action by pre-conjugating the therapeutic agent to ASGPR-targeting ligands before administration. This pre-preparation ensures that upon injection, the agent is immediately directed to liver cells for rapid uptake and clearance. The preliminary conjugation step eliminates the need for the body to naturally process and clear the antibody through slow metabolic pathways, dramatically accelerating the clearance rate.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively reduce the concentration of antibodies involved in transplant rejection, autoimmune diseases, and allergies by at least 50% within 12 to 48 hours, inducing immune tolerance and clearing causative proteins or peptides from the blood.
Implementation Method 1
The compositions can be used to facilitate uptake by liver cells, such as hepatocytes and LSECs
Data Source
AI summary
Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.